Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC. Richardson PG, et al. Among authors: cavenagh jd. Br J Haematol. 2007 Jun;137(5):429-35. doi: 10.1111/j.1365-2141.2007.06585.x. Epub 2007 Apr 19. Br J Haematol. 2007. PMID: 17451408 Free article. Clinical Trial.
Thalidomide in multiple myeloma: current status and future prospects.
Cavenagh JD, Oakervee H; UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces. Cavenagh JD, et al. Br J Haematol. 2003 Jan;120(1):18-26. doi: 10.1046/j.1365-2141.2003.03902.x. Br J Haematol. 2003. PMID: 12492572 Free article. No abstract available.
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma.
Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation. Shaw BE, et al. Br J Haematol. 2003 Dec;123(5):886-95. doi: 10.1046/j.1365-2141.2003.04714.x. Br J Haematol. 2003. PMID: 14632780 Free article.
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT). Hunter HM, et al. Br J Haematol. 2005 Feb;128(4):496-502. doi: 10.1111/j.1365-2141.2004.05330.x. Br J Haematol. 2005. PMID: 15686458 Free article.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.
Bortezomib for multiple myeloma.
Popat R, Joel S, Oakervee H, Cavenagh J. Popat R, et al. Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. doi: 10.1517/14656566.7.10.1337. Expert Opin Pharmacother. 2006. PMID: 16805719 Review.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Richardson PG, et al. Blood. 2007 Nov 15;110(10):3557-60. doi: 10.1182/blood-2006-08-036947. Epub 2007 Aug 9. Blood. 2007. PMID: 17690257 Free article. Clinical Trial.
200 results